Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The Impact of the COVID-19 Pandemic on Breast Imaging

Phoebe E. Freer, MD, FSBI

INTRODUCTION

Starting in Wuhan, China, followed quickly in the United States in January 2020, an outbreak of a novel coronavirus, or COVID-19, escalated to a global pandemic by March. Significant disruptions occurred to breast imaging, including deferred screening mammography, triaging diagnostic breast imaging, and changes in breast cancer care algorithms. This article summarizes the effect of the global pandemic—and efforts to curtail its spread—on both breast cancer care and on breast imaging practices including effects on patients, clinical workflow, education, and research.

INITIAL RESPONSE: ROUTINE HEALTH CARE DEFERRED

The approach to the handling of COVID-19 has been fluid, as understanding of the pathophysiology, clinical spectrum and severity of illness, and possible preventions and treatment of the virus have evolved.1,2

Early Response: Concerns for Mammography in COVID-19

Shortly after the first outbreaks in the United States on the Diamond Princess Cruise Ship, in Seattle and New York, on the heels of large outbreaks in China and Italy, the main prevention strategy of “social distancing” was adopted by the World Health Organization.3 By April 2020, 33 states had state mandated “stay-at-home-orders.” The Centers for Disease control (CDC) issued recommendations to reschedule nonurgent patient care and delay screenings in an effort to minimize risks to patients and health care workers (HCWs).4 Although social distancing measures varied regionally, most of the school systems, churches, and businesses were closed in March or April 2020, often moving to virtual encounters. Leaders in breast imaging and radiology departments discussed the best ways to protect patients, protect HCWs, and conserve personal protective equipment (PPE) and ventilators to be

KEYWORDS

• COVID-19 • Pandemic • Breast cancer • Breast imaging • Delayed care • Radiology finances

KEY POINTS

• The COVID-19 pandemic starting in the United States in 2020 has had practice-changing effects on cancer care, clinical workflow, education, research, and radiology finances.
• Significant volume reductions and delays occurred to breast imaging, with screening mammography being the hardest hit.
• Long-term outcomes from changes in breast cancer management algorithm during the pandemic are yet to be determined.
• Increased telehealth and telecommuting will likely continue after the pandemic is over in some fashion.
• Radiology practices and hospitals sustained large financial ramifications from the effects of the pandemic.
used for patients with COVID-19. Many sites began rescheduling screening mammography patients, some diagnostic or biopsy cases, or even delaying breast surgeries in an ad hoc fashion. Varied interpretations of the CDC, WHO, and the varied state policies led to nonuniform disruptions in patient care, in some cases varying within the same large cities.

On March 24th, news reports of potential danger to mammography technologists from work exposures were released, with a death of a mammography technologist in Georgia from COVID-19, a possible work exposure. HCWs were confirmed to be high risk for COVID-19 infections (up to 10%) from initial data in early outbreaks in China, Italy, and Spain. The National Comprehensive Cancer Network (NCCN) issued guidelines for health care worker safety early in the pandemic, based on WHO recommendations. In a study rating different professions’ risk of contracting COVID-19 from work, radiology technologists were one of the highest (a score of 84 out of 100), and then sonographers (80 out of 100). Mammo- graphic technologists likely have an even higher risk, as they are unable to maintain social distancing (2 m or 6 feet) during positioning.

Quickly, breast radiologists and technologists had palpable concerns regarding the need to protect HCWs and patients during screening, and firm statements were released by national organizations with the American Society of Breast Surgeons (ASBrS) and American College of Radiology (ACR) Joint Statement on Breast Screening Exams During the COVID-19 Pandemic and the Society of Breast Imaging Statement on Breast Imaging during the COVID-19 Pandemic. The panel represents a joint collaboration from the ASBrS, the National Accreditation Program for Breast Centers (NAPBC), the NCCN, the Commission on Cancer, and ACR. The main goals of the Consortium recommendations were to “preserve hospital resources for virus-inflicted patients by deferring BC treatments without significantly compromising long-term outcomes for individual BC patients”. Patients were placed into categories based on severity of symptoms or illnesses with algorithms for chemotherapy and surgery outlined based on disease process.

**A More Standardized Approach to Deferred Care**

By March, the Canadian Society of Breast Imaging and Canadian Association of Radiologists Joint Position Statement on COVID-19 recommended that all screening mammography and MR imaging be deferred for at least 6 to 8 weeks and suggested triaging the diagnostic cases, deferring ones that were not highly suspicious for cancer. The Society of Breast Imaging followed suit with a statement that was broader and less prescriptive but also recommended delaying screening by “several weeks or a few months.” Other international societies published similar statements.

Multidisciplinary care algorithms changed the management of breast cancer during the pandemic in response to need to balance the urgency of care against the risks to patients and HCWs secondary to potential COVID-19 exposures. Surgeries were postponed both to limit COVID-19 transmission as well as to preserve resources such as ventilators, PPE, and hospital beds. The American College of Surgeons (ACS) and the Society of Surgical Oncology released triage guidelines recommending an interim cancellation of most routine surgeries, while still performing breast surgeries for those in more urgent cases. Some centers, such as Magee-Breast Cancer Program and Johns Hopkins published multidisciplinary algorithms of how best to triage patients with breast cancer, broken down by subtypes. Other published tools suggested risk-stratifying patients for breast surgery with the purpose of causing few deleterious effects in patients recommended for postponement.

In early April, a multidisciplinary group of breast cancer experts in the United States formed the COVID-19 Pandemic Breast Cancer Consortium and released its recommendations for prioritization, treatment, and triage of patients with breast cancer during the COVID-19 pandemic. The panel represents a joint collaboration from the ASBrS, the National Accreditation Program for Breast Centers (NAPBC), the NCCN, the Commission on Cancer, and ACR. The main goals of the Consortium recommendations were to “preserve hospital resources for virus-inflicted patients by deferring BC treatments without significantly compromising long-term outcomes for individual BC patients”. Patients were placed into categories based on severity of symptoms or illnesses with algorithms for chemotherapy and surgery outlined based on disease process.

**REOPENING OF ROUTINE CARE**

By July 2020, as the pandemic proved lasting and PPE supplies improved nationwide, consensus guidelines shifted to avoid delays in care and focused instead on how to better protect patients and workers. Leaders in breast cancer made evidence-based pleas to cease labeling patients with cancer as a high-risk population in order to avoid delays in their diagnosis and treatment.
Numerous consensus statements and guidelines regarding how to best balance the risks of COVID-19 transmission to patients and HCWs against the risks of delaying care have been published. The European Society for Medical Oncology Guidelines include increasing telehealth appointments (noting in person visits are needed for new patients with cancer or urgent infections/postoperative complications) and specific guidance for management and advised that the risk/benefit balance for most patients favored continued administration of systemic therapies and chemotherapies, with additional precautions when possible (e.g., choosing less immunosuppressive therapies, regimens requiring fewer appointments). Numerous other guidance documents have emerged fluidly including from American Society of Clinical Oncology (ASCO) and an online resource from ASCO, and others globally.

Although the recommendations for the management of breast cancer change the order and timing of breast cancer treatments, the goals have remained to change these algorithms in ways that do not affect long-term outcomes or chances for a cure. For example, surgery should remain the primary option for small triple-negative breast cancers that did not require chemotherapy based on pre-COVID-19 algorithms. In addition, patients with progressive disease on medical therapy should have surgery. Further patients who are competing their neoadjuvant regimens or patients who did not respond to neoadjuvant therapy should receive surgery.

Prophylactic measures were implemented with guidance from the CDC, for protecting patients and HCWs, including social distancing where possible, masking both patients and HCWs, decreasing the number of scheduled patients, increasing space in waiting areas, and implementing disinfection protocols. Nearly all imaging centers implemented preappointment screening for symptoms of COVID-19, most requiring temperature screening at some point during the pandemic and a few even required COVID-19 negative testing before a breast interventional procedure (although many centers required COVID-19 negative testing before breast surgeries).

**CHANGES IN FOOD AND DRUG ADMINISTRATION INSPECTIONS DURING COVID-19**

Initially, the FDA halted inspections of mammography facilities required by the Mammographic Quality Standards Act in mid-March, 2020. In addition, the ACR granted automatic extensions and halted in-person inspections for sites where accreditation was expiring. As the reopening phase began, the FDA announced that it would restart inspections at facilities in locations that were not as affected by the pandemic on July 20th, although it did not actually start them then. It recommended that state inspections could start based on individual state guidance at the end of June 2020, guided by an advisory system to take into account the extent of the outbreak in that location combined with how critical the inspection would be.

**BREAST CANCER AS A COMORBIDITY FOR COVID-19 SEVERE OUTCOMES/FATALITIES**

Initially, concern existed that patients with breast cancer, especially advanced or metastatic breast cancer, may be more susceptible to severe outcomes with COVID-19. Many of the most common chemotherapy regimens used to treat breast cancer are known to cause immunosuppression. Further, patients undergoing cancer care have more visits and therefore more exposures to HCWs and patients, potentially making them more at risk of being infected with COVID-19. Initial studies from Wuhan, China showed worse outcomes from COVID-19 in patients with cancer and suggested caution with cancer care during the pandemic. In one study of 1524 patients from the Wuhan outbreak, patients with cancer had more than double the risk of contracting COVID-19 than patients without (odds ratio [OR], 2.31; 95% confidence interval [CI], 1.89 to 3.02). In another early study from the Wuhan experience, the relative risk of dying or being admitted to the intensive care unit with COVID-19 in patients with cancer was 5.4 (95% CI 1.8–16.2). Moreover, patients with cancer had a higher relative risk of requiring intubation, across all age ranges. The mortality rate of COVID-19 in patients with cancer has ranged from 11% to 28% in reported studies, compared with the 1.4% mortality rate reported in the general population from the initial Wuhan studies. However, not all patients with cancer have the same risks, as a patient with an early stage breast cancer may not have the COVID-19 risks as a patient with end-of-life stage IV breast cancer. This was confirmed by one study of 900 patients with cancer and COVID-19 that found that having active cancer that was progressing (as opposed to remission) and having a worse performance status were associated with increased risk of mortality.

As the pandemic has unfolded, registries for patients with cancer and COVID-19 have been...
developed in an attempt to better understand the risk to patients with cancer, as initial reports on outcomes were limited to single institutional or smaller studies. An international database was established to study the risks of COVID-19 on patients with cancer from the United States, Canada, and Spain with underlying cancer (the COVID-19 and Cancer Consortium Database or CCC19). And ASCO developed its own registry to be able to share data rapidly and contribute to evidence-based decision-making for patients with cancer during the pandemic.

Initial reports from mid-March through mid-April of the CCC19, including more than 900 patients with cancer (21% breast cancer) and COVID-19 found that although the 30-day all-cause mortality for the entire population with cancer and COVID-19 was high, associated with both general and cancer-specific risk factors, the actual risk in patients with solid tumors (ie, breast cancer) was not significantly higher. This study also confirmed recent cancer surgery did not affect the mortality rate from concurrent infections with COVID-19. A large cohort study of 800 patients with cancer with COVID-19 in the United Kingdom (UK Coronavirus Cancer Monitoring Project), at a similar time frame of the pandemic, found that although the mortality rate was 28%, when adjusted for age and other comorbidities, the presence of cancer alone did not increase the mortality rate from COVID-19. Importantly, the use of chemotherapy before COVID-19 infection did not affect mortality, neither did the use of hormonal, targeted, and, immune therapies, or radiation.

Thus, although it may be possible that some patients with cancer have a propensity toward worse outcomes with COVID-19, it does not seem likely that cancer treatments such as chemotherapy, hormonal therapy, radiation, and surgery predispose patients to more serious outcomes from COVID-19. If care is taken for protective measures for the patients and HCWs as outlined in different care algorithms, breast cancer treatment should continue during the pandemic, especially in light of the unknown timeframe of the crisis.

EFFECTS OF DELAYING CARE ON PATIENTS WITH BREAST CANCER

Not only did multidisciplinary care algorithms force patients into delaying care during the pandemic but patients also self-selected to delay care. Nearly 4 out of 10 patients said the economic changes from the pandemic affected their ability to pay for medical care. A survey by ACEP demonstrated almost one-third of patients (29%) delayed or avoided going to the emergency room in March/April 2020 in order to avoid COVID-19 exposures. Four out of five patients were fearful of contracting the virus from a patient or HCW if they did go. Greater than 81% of survey participants acknowledged practicing social distancing. In an Italian study, during the height of the outbreak, there was a significant increase in patients refusing to undergo diagnostic appointments and breast biopsies at a major cancer center.

In another 600 breast care patients surveyed, almost 80% stated they had routine and follow-up appointments delayed, two-thirds had reconstruction surgery delayed, and 60% had delayed diagnostic imaging. Therapies that required in-person visits to the hospital (radiation, chemotherapy infusion, and surgical lumpectomies) were more likely to be delayed than those that could be obtained through telehealth appointments or a prescription pick-up. Medicare and Medicaid Services and private insurers expanded telehealth benefits to patients covering increased virtual visits. On average, about 30% of patients experienced delays in the mainstays of breast cancer treatment including lumpectomies, radiation therapy, and chemotherapy.

Breast cancer surgeries declined significantly during the early parts of the global pandemic. In data from 55 breast centers in 27 states, it was noted that the average decline in breast surgery clinic appointments over the first few weeks was 21% with a nadir of 40% from baseline and a near 20% decline in new breast cancer surgery consultations in the surgery clinics. Similarly, breast cancer genetics appointments declined, ranging between 25% and 30%. In one study from Wuhan, China, more than half of the patients receiving radiation therapy were unable to complete their regimens during the lockdowns. The pandemic increased the use of neoadjuvant and hormonal therapies before surgery, as well as increased genotypic profiling, secondary to deferrals of surgeries. In another study from the Netherlands one-third of patients noted that the pandemic affected their cancer care, with most of these noting a shift to telehealth consultations. Chemotherapy was also affected in about one-third of these patients.

The long-term physical and psychosocial ramifications of these delays remain to be determined. One study demonstrated that more than half of the patients with cancer were concerned the delays or discontinuation of care during the pandemic affected their outcomes. Oncologic patients noted anxieties regarding whether they were at increased risk of worse outcomes with COVID-19, as well as anger and worry from delays or interruptions in their care during COVID-19. Some patients even stated that the changes in
their care encountered sounded “like a death sentence” or made them “feel like my care and health aren’t important to you”.55 These patient perceptions, whether accurate or not, will need to be addressed as the pandemic unfolds.55,56

The mental health effects of limiting care during this pandemic, and potentially in future crises, on both cancer specialists and patients, who are used to unlimited resources for health care, may be far reaching. Having consensus guidelines to guide fair decision-making and developing empathic communication with regard to these issues is important.57 Education and shifts in mind-sets to prioritize the maximum health benefit for the community over the individual may be necessary in a country used to unlimited resources. Guidelines have been developed for low resource communities that may prove useful.58,59

It is unclear what effects these COVID-19 provoked changes in cancer screening and management will have on long-term cancer outcomes. In the United States, an estimated additional 87,001 deaths occurred in March and most of April 2020 compared with the last 6 years, of which 35% (30,755) were not directly attributable to COVID-19 (and in 14 states, >50% of excess deaths frame were not attributable).60 Almost half (48%) of US people surveyed had a family member who had delayed medical care during the pandemic, with 10% stating that that member’s medical condition worsened during the delay.61 One modeling study of 6281 new stage 1 to 3 cancer cases in the United Kingdom who were delayed multidisci- plinary workup during the pandemic suggested that an additional 181 lives and 3316 life years would be lost with a conservative estimate of only 25% of cases backlogged for 2 months.62

During the early phases of the pandemic, the number of new cancers diagnosed decreased.63,64 This drop was likely secondary to patients not presenting for care and not a true drop in incidence. Thus, these cancers will come to the radar eventually at a greater size or stage than they would have with earlier detection, which may affect prognosis. A model that assumed only a 6-month disruption of care during the pandemic estimated the potential excess deaths from breast and colorectal cancer secondary to the pandemic disruptions in care demonstrates an excess of more than 10,000 deaths in the next decade, peaking in the first few years.65 This model does not account for the increased morbidity, with possible more extensive surgeries including more mastectomies or more need for chemotherapy secondary to later presentations of disease.

Previous studies have demonstrated worsened outcomes during economic downturns, and in times of stress, and so it is likely the effects on breast cancer detection and management combined with the economic and societal effects of the pandemic will lead to effects on long-term outcomes.66 It is also plausible that if there are not measurable deleterious effects from these delays, then reimbursements for care may be renegotiated or guidelines may shift to reduce care.

EFFECTS ON HOSPITALS AND RADIOLOGISTS OF CHANGES IN CARE

The COVID-19 pandemic has had marked economic effects on the health care system, academic radiology departments, and radiology practices. A survey conducted by ACR and the Radiology Business Management Association reported that 97.4% of 228 radiology practices (urban, academic, and rural) experienced declines in imaging volume in March/April 2020, with a drop of greater than 90% of elective procedures and 60% of urgent procedures.13 One-third of academic radiology chairs reported a near two-thirds decrease in volume with some reporting an 80% drop in hard hit areas.34 Greater than 82% of chairs had at least a 50% decrease in total radi- ology volume at the nadir.34

Breast imaging was disproportionately affected by postponed cases. The largest health care sys- tem in New York reported a drop of 88% affecting all modality types, with mammography use plummeting by 94%, MR imaging 74%, and ultrasound 64%.67 In another study of 6 academic medical centers across the United States, 3 centers in re- gions with lower rates of COVID-19, radiology vol- umes declined steeply from calendar week 11 to 16 with a range of 40% to 70% total volume drop at the lowest drop.68 Of those drops, screening mammography was among the most significant drop, as well as slowest in recovering. The reduction in screening mammography went as far as 99% in weeks 15 and 16. Diagnostic mammography volumes did not drop as dramati- cally, however still hit a low of 85% volume decrease at the nadir in week 16.68

On gradual reopenings of care (in May–July in most centers), a significant backlog of past studies had built. In addition, significant changes in sched- uling with increased evening or weekend hours, changes in protocols for shorter MR imaging scan times,68 and off-loading studies from hospi- tals and cancer centers to protect higher risk pa- tients were required to allow for more spacing. Changes to patient registration and check-in, pre- screening for symptoms, PPE requirements, and disinfection protocols were instituted briskly. One hundred percent of academic radiology...
departments reported reorganizing the waiting rooms and dressing areas to comply with social distancing mandates.34

Radiology practices restructured reading rooms and implemented home PACS. Some practices shifted rapidly to home PACS, moving from 100% of radiologists onsite to 80% reading from home within a few weeks.65 However, for breast imaging, this process is more complicated and expensive due to quality compliance requirements, the need for high-resolution monitors, and the need to be on site for diagnostic and interventions and happened at much lower levels. Telehealth increased in general, for patient surgery, oncology, and genetics appointments, as well as for virtual multidisciplinary tumor boards. Educational conferences and lectures moved to virtual platforms such as Webex, Microsoft Teams, and Zoom.13,70 The effect of increased telecommuting and telehealth remain unclear. Telecommuting may increase radiologist morale, flexibility, and even potentially productivity, or alternatively it may decrease collaborations, interfacing with multidisciplinary colleagues, educational value, or productivity.71 About half of the radiologists surveyed nationwide believed that teleradiology would continue and lead to increased efficiency.13

The marked reductions in volume have devastating financial implications to practices. Half of the health care practices in California furloughed or laid off employees and almost two-thirds reduced staff hours.61,72 In academic practices, a quarter had furloughed or laid off staff.34 Significant reductions in radiologist and staff incomes (in about 50% of practices in one survey), personal and academic protected time, research endeavors, workload, hours, professional funds, bonuses and financial incentives, and retirement allocations occurred amid hiring freezes and workspaces changes.13 In a survey of 228 practices from across the country, there were mean reductions in both receipts and gross charges on average about 50%,13 and greater than 70% of respondents reported applying for some sort of governmental financial relief. Although emergency governmental funds for financial relief were dispensed to hospitals and health care organizations through The Coronavirus Aid, Relief, and Economic Security Act and the Paycheck Protection Program and Health Care Enhancement Act (on the order of nearly $200 billion dollars), these funds are likely not enough to prevent lasting financial implications from the significant disruptions in volume and care.73,74 Although practices are recovering, some near fully, as of September 2020, the anticipated time to full recovery remains unknown.

Effects on radiologist’s mental health through this crisis have been significant. More than 60% of 600 radiologists in 44 states rated their anxiety as a 7 out of 10 during the pandemic.75 In addition to having work and economic worries, some radiologists and staff were redeployed in the early days in hotspots to better serve COVID-19 patient care. In addition, many radiologists have had increased burdens at home with unexpected need to provide childcare and teaching duties for virtual schooling amid school and childcare care closures.76 In addition, more than one-third of radiologists thought that they did not have adequate teleradiology capabilities during the pandemic, and about half said they did not have adequate PPE for themselves or their patients.75 Mental stress regarding personal and family health, disruptions to travel and schedule, and family members with lost jobs or decreased income also affects the potential for long-term burnout in radiologists to increase, and mitigation strategies for burnout should be used.77

DELAYS IN CLINICAL RESEARCH EDUCATION AND ACADEMIC MEETINGS

Radiology education has also been significantly disrupted during the COVID-19 pandemic, including the need for redeployment, changes to reading rooms and social distancing, and cessation of in person conferences and didactic learning.78 Some radiologists, especially residents early in training, were redeployed to other areas, particularly hard-hit urban environments such as New York and Boston, with some medical students even graduating early to join the front lines in caring for COVID-19–infected patients. Approximately 40% of radiologists in one survey thought that the shift to socially distant interpretations and conferences had a deleterious effect on resident and fellow education.13

Hundreds of scientific and medical conferences including dozens of radiology conferences were canceled or moved to virtual formats.79 Significant impacts on networking, collaboration, committee work, vendor marketing, scientific presentations, and sharing of research are likely that may affect scientific progress as well as career choices.80 Many radiologists were placed on institutional or state travel bans. Virtual grand rounds and virtual interviews both for education and for hiring were implemented during the pandemic. The cost and time savings of such virtual practices may prove to be practice changing after the pandemic is over.
Initially, most academic centers and universities suspended research, especially all trials involving patients or in-person interactions. Guidance on how best to preserve clinical trials, and maintain integrity for those interrupted, was offered by the senior editorial staff at JAMA. The FDA offered direction for those trials that may be disrupted. Additional suggestions on how to avoid overestimation of disease-free survival if patients skip assessments and to report results from data during the pandemic separately from date before the pandemic continue to be offered. In contrast, the National Cancer Institute intentionally kept functioning at 100% and stressed the importance of maintaining research to allow patients to have access to clinical trials and to maintain scientific progress, as well as to study the effects of COVID-19 in patients with cancer. The National Cancer Institute (NCI) showed increased flexibility for prior minor infractions (such tests as a missed blood draw), recognizing that they may be necessary during COVID-19 to help maintain social distancing best practices for the patient. Some of the flexibility extended to clinical trials during the pandemic such as virtual, instead of in-person, visits for enrollment or assessments, the ability to receive tests and laboratory draws at sites closer to the patient that are not part of the trial sites, and decreases in the administrative tasks required prepandemic may carry over to the postpandemic world, perhaps making clinical trials more accessible to the general population.

Of note, the pandemic led to the creation of unique opportunities for the creation of collaborative, crowdsourced research endeavors and databases, including the COVID-19 and Cancer Consortium, among others, collecting real-time data for observational trials.

LONG-TERM RAMIFICATIONS AND REBUILDING

The final economic costs of the pandemic on the health care industry will likely be colossal. One study proposes the direct medical costs will approach $165 billion dollars if only 20% of the population is infected (53.8 million symptomatic cases) and would continue to cost up to a total of almost $215 billion in indirect costs in the year after discharge. This figure will increase if the percent infected increased greater than that. Nationally, there has been significant deleterious effects on the economy including almost 17 million Americans filing for unemployment in a 3-week period over March/April alone, although with claims decreasing continually since that peak. Whether or not COVID-19 will continue to circulate in the population with annual or seasonal outbreaks or whether this will be an outbreak that has mostly cycled through the population with a return to closer to normal by 2022 or so remains unclear and debated yet at the time of this writing.

What is clear is that without a vaccine and other treatments, social distancing and PPE with masks and other protections for HCWs are likely to remain the primary weapons against the virus and will likely continue to play a part in daily life and in radiology practices and patient care in breast imaging centers for a while yet to come. What the future looks like on the other side of the pandemic remains unclear but will involve significant effects on both COVID-19- and non-COVID-19-related health outcomes, mental health outcomes, the national and global economy, radiology practices and breast centers, and on cancer outcomes, screening rates, and cancer management and treatment protocols.

CLINICS CARE POINTS

- If care is taken for protective measures for the patients and HCWs as outlined in different care algorithms, breast cancer treatment should continue during the pandemic, especially in light of the unknown timeframe of the crisis.
- It is unclear what effects these COVID-19 provoked changes in cancer screening and management will have on long term cancer outcomes.
- Radiology volumes dropped drastically during the early weeks of the pandemic, with the most dramatic reductions in screening mammography which came to a near complete halt for a few weeks in most places.
- Mental stress and workload changes increase the potential for long term burnout in radiologists to increase and mitigation strategies for burnout should be employed.

REFERENCES

1. Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med 2020;382:929–36.
2. Coronavirus Resource Center. Johns Hopkins University School of Medicine. Available at: https://coronavirus.jhu.edu. Accessed September 10, 2020.
3. World Health Organization. Responding to community spread of COVID-19: interim guidance, 7 March 2020. World Health Organization. Available at: https://apps.who.int/iris/handle/10665/331421. Accessed September 10, 2020.
4. Framework for Healthcare Systems Providing Non-COVID-19 Clinical Care During the COVID-19 Pandemic. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/framework-non-COVID-care.html. Updated June 30th. Accessed September 10, 2020.

5. Moy L, Toth HK, Newell MS, et al. Response to COVID-19 in Breast Imaging. J Breast Imaging 2020;2(3):180–5.

6. Sharpe RE Jr, Kuszyk BS, Mossa-Basha M, For the RSNA COVID-19 Task Force. Special Report of the RSNA COVID-19 Task Force: The Short- and Long-Term Financial Impact of the COVID-19 Pandemic on Private Radiology Practices. Radiology 2020. https://doi.org/10.1148/radiol.2020205217.

7. The coronavirus claims two Georgia healthcare workers. 2020. Available at: https://www.ajc.com/news/virus-claims-two-georgia-healthcare-workers/XTijtgzE6z2gcoZ7QLvPZN/. Accessed September 8, 2020.

8. Nguyen LH, Drew DA, Graham MS, et al. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. Lancet Public Health 2020;5:e475–83.

9. Cinar P, Kubal T, Freifeld A, et al. Safety at the Time of the COVID-19 Pandemic: How to Keep our Oncology Patients and Healthcare Workers Safe. J Natl Compr Canc Netw 2020;1–6. https://doi.org/10.6004/jnccn.2020.7572.

10. Lu M. The front line: visualizing the occupations with the highest COVID-19 risk. 2020. Available at: https://www.visualcapitalist.com/the-front-line-visualizing-the-occupations-with-the-highest-COVID-19-risk/. Accessed September 9, 2020.

11. ASBrS and ACR Joint Statement on Breast Screening Exams During the COVID-19 Pandemic. 2020. Available at: https://www.sbi-online.org/Portals/0/Position%20Statements/2020/society-of-breast-imaging-statement-on-breast-imaging-during-COVID19-pandemic.pdf. Accessed September 9, 2020.

12. Society of Breast Imaging Statement on Breast Imaging during the COVID-19 Pandemic. 2020. Available at: https://www.sbi-online.org/Portals/0/Position%20Statements/2020/society-of-breast-imaging-statement-on-breast-imaging-during-COVID19-pandemic.pdf. Accessed September 9, 2020.

13. Malhotra A, Wu X, Fleishon HB, et al. Initial Impact of Coronavirus Disease 2019 (COVID-19) on Radiology Practices: An ACR/RBMA Survey [published online ahead of print, 2020 Aug 4]. J Am Coll Radiol 2020. https://doi.org/10.1016/j.jacr.2020.07.028.

14. Canadian Society of Breast Imaging and Canadian Association of Radiologists Joint Position Statement on COVID-19. 2020. Available at: https://csbi.ca/wp-content/uploads/2020/03/Covid-19-statement-CSBI_CAR-1.pdf. Accessed. September 14, 2020.

15. Society of Breast Imaging Statement on Screening in a Time of Social Distancing. 2020. Available at: https://www.sbi-online.org/Portals/0/Position%20Statements/2020/SBI-statement-on-screening-in-a-time-of-social-distancing_March-17-2020.pdf. Accessed September 10, 2020.

16. Pediconi F, Mann RM, Gilbert FJ, et al. on behalf of the EUSOBI Executive Board. EUSOBI recommendations for breast imaging and cancer diagnosis during and after the COVID-19 pandemic. 2020. Available at: https://www.eusobi.org/content-eusobi/uploads/EUSOBI-Recommendations_Breast-Imaging-during-COVID.pdf. Accessed September 9, 2020.

17. Pediconi F, Galati F, Bernardi D, et al. Breast imaging and cancer diagnosis during the COVID-19 pandemic: recommendations from the Italian College of Breast Radiologists by SIRM. Radiol Med 2020;125(10):926–30.

18. American College of Surgeons. COVID-19: Guidance for Triage of Non-Emergent Surgical Procedures. 2020. Available at: https://www.facs.org/covid-19/clinical-guidance/triage. Accessed September 10, 2020.

19. Bartlett DL, Howe JR, Chang G, et al. Management of Cancer Surgery Cases During the COVID-19 Pandemic: Considerations. Ann Surg Oncol 2020;27:1717–20.

20. Soran A, Bruisky A, Gimbel M, et al. Breast Cancer Diagnosis, Treatment and Follow-Up During COVID-19 Pandemic. Eur J Breast Health 2020;16(2):86–8.

21. Sheng JY, Santa-Maria CA, Mangini N, et al. Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach [published online ahead of print, 2020 Jun 30]. JCO Oncol Pract 2020. https://doi.org/10.1200/OP.20.00364.

22. Smith BL, Nguyen A, Korotkin JE, et al. A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry. Breast Cancer Res Treat 2020. https://doi.org/10.1007/s10549-020-05792-2.

23. Dietz JR, Moran MS, Isakov SJ, et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic the COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat 2020. https://doi.org/10.1007/s10549-020-05644-z.

24. American College of Surgeons, American Society of Anesthesiologists. Association of periOperative Registered Nurses, American Hospital Association. Joint Statement: Roadmap for Resuming Elective Surgery after COVID-19 Pandemic. 2020. Available at: https://www.facs.org/covid-19/clinical-guidance/roadmap-elective-surgery. Accessed September 9, 2020.
25. Curigliano G, Banerjee S, Cervantes A, et al. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus [published online ahead of print, 2020 Jul 31]. Ann Oncol 2020. https://doi.org/10.1016/j.annonc.2020.07.010.

26. Hanna TP, Evans GA, Booth CM. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nat Rev Clin Oncol 2020;17:268–70.

27. Chan JJ, Sim Y, Ow SGW, et al. The impact of COVID-19 on and recommendations for breast cancer care: The Singapore experience. Endocr Relat Cancer 2020;27(9):R307–27.

28. Curigliano G, Cardoso MJ, Poortmans P, et al. Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic. Breast 2020;52:8–16.

29. de Azambuja E, Trapani D, Loibl S, et al. ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. ESMO Open 2020;5(Suppl 3):e000793.

30. ESMO. The ESMO-MCBS Score Card esmo.org. 2020. Available at: https://www.esmo.org/guidelines/esmo-mcbs/esmo-magnitude-of-clinical-benefit-scale. Accessed September 9, 2020.

31. ASCO Special Report: A Guide to Cancer Care Delivery During the COVID-19 Pandemic. 2020. Available at: https://www.asco.org/sites/new-www.asco.org/files/content-files/2020-ASCO-Guide-Cancer-COVID19.pdf. Accessed September 9, 2020.

32. ASCO Coronavirus Resources. Available at: https://www.asco.org/asco-coronavirus-information. Accessed September 10, 2020.

33. Spring LM, Specht MC, Jimenez RB, et al. Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic. N Engl J Med 2020;383(3):262–72.

34. Siegal DS, Wessman B, Zadorozny J, et al. Operational impact of SARS-CoV-2 infection: a nationwide analysis in China. Ann Oncol 2020;31(7):894–901.

35. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323(13):1239–42.

36. Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 2020;31(7):894–901.

37. Lee LY, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study [published correction appears in Lancet. 2020;395(10253):758]. Lancet 2020;395(10241):1907–18.

38. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20.

39. American Society of Clinical Oncology. ASCO Survey on COVID-19 in Oncology (ASCO) Registry. Available at: https://www.asco.org/asco-coronavirus-information/coronavirus-registry. Accessed September 10, 2020.

40. Lee LY, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study [published correction appears in Lancet. 2020;395(10241):1919–26].

41. Printz C. When a global pandemic complicates cancer care: Although oncologists and their patients are accustomed to fighting tough battles against a lethal disease, Coronavirus Disease 2019 (COVID-19) has posed an unprecedented challenge. Cancer 2020;126(14):3171–3.

42. American College of Emergency Physicians COVID-19. 2020. Available at: https://www.emergencyphysicians.org/globalassets/emphysicia ns/all-pdfs/acep-mc-COVID19-april-poll-analysis.pdf. Accessed September 8, 2020.

43. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21(3):335–7.

44. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20.

45. Mehta V, Goel S, Kabarriti R, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov 2020. https://doi.org/10.1158/2159–8290.CD-20–0516.

46. Miyashita H, Mikami T, Chopra N, et al. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol 2020. doi:10.1016/j.annonc.2020.04.006.

47. Printz C. When a global pandemic complicates cancer care: Although oncologists and their patients are accustomed to fighting tough battles against a lethal disease, Coronavirus Disease 2019 (COVID-19) has posed an unprecedented challenge. Cancer 2020;126(14):3171–3.

48. American College of Emergency Physicians COVID-19. 2020. Available at: https://www.emergencyphysicians.org/globalassets/emphysicians/all-pdfs/acep-mc-COVID19-april-poll-analysis.pdf. Accessed September 8, 2020.
Patients’ Decision-making Process. In Vivo 2020;34(3 Suppl):1651–9.
50. Papautsky EL, Hamlish T. Patient-reported treatment delays in breast cancer care during the COVID-19 pandemic. Breast Cancer Res Treat 2020. https://doi.org/10.1007/s10549-020-05828-7.
51. Medicare telemedicine health care provider fact sheet. 2020. Available at: https://www.cms.gov/newsroom/fact-sheets/medicare-telemedicine-health-care-provider-fact-sheet. Accessed September 8, 2020.
52. Yin K, Singh P, Drohan B, et al. Breast imaging, breast surgery, and cancer genetics in the age of COVID-19 [published online ahead of print, 2020 Aug 4]. Cancer 2020. https://doi.org/10.1002/cncr.33113.
53. Xie C, Wang X, Liu H, et al. Outcomes in Radiotherapy-Treated Patients With Cancer During the COVID-19 Outbreak in Wuhan, China [published online ahead of print, 2020 Jul 30]. JAMA Oncol 2020;e202783. https://doi.org/10.1001/jamaoncol.2020.2783.
54. de Joode K, Dumoulin DW, Engelen V, et al. Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients’ perspective. Eur J Cancer 2020;136:132–9.
55. Gharzai LA, Resnicow K, An LC, et al. Outcomes in Radiotherapy-Treated Patients With Cancer During the COVID-19 Pandemic: A Qualitative Study [published online ahead of print, 2020 Aug 6]. JAMA Oncol 2020;e202980. https://doi.org/10.1001/jamaoncol.2020.2980.
56. Oncology Language for the COVID-19 Pandemic. 2020. Available at: https://www.nccn.org/covid-19/pdf/Oncology%20Language-Communicating%20Changes%20in%20Delivery%20of%20Care.pdf. Accessed September 8, 2020.
57. Emanuel EJ, Persad G, Upshur R, et al. Fair Allocation of Scarce Medical Resources in the Time of Covid-19. N Engl J Med 2020;382(21):2049–55.
58. DeBoer RJ, Fadelu TA, Shulman LN, et al. Applying Lessons Learned From Low-Resource Settings to Prioritize Cancer Care in a Pandemic. JAMA Oncol 2020;6(9):1429–33.
59. IJzerman M, Emery J. Is a delayed cancer diagnosis a consequence of COVID-19? 2020. Available at: https://pursuit.unimelb.edu.au/articles/is-a-delayed-cancer-diagnosis-a-consequence-of-covid-19. Accessed September 9, 2020.
60. Kaufman HW, Chen Z, Niles J, et al. Changes in the Number of US Patients With Newly Identified Cancer Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic. JAMA Netw Open 2020; 3(8):e2017267.
61. Hamel L, Kearney A, Kirsinger A, et al. Early-Stage Radiology Volume Effects and Considerations with the Coronavirus Disease 2019 (COVID-19) Pandemic: Adaptations, Risks, and Lessons Learned. J Am Coll Radiol 2020;17(9):1086–95.
62. Norbash AM, Moore AV Jr, Recht MP, et al. Economic downturns, universal health coverage, and cancer mortality in high-income and middle-income countries, 1990-2010: a longitudinal analysis. Lancet 2016;388(10045):684–95.
63. Shaffer NE, COVID-19 and cancer. Science 2020; 368(6497):1290.
64. Maruthappu M, Watkins J, Noor AM, et al. Economic downturns, universal health coverage, and cancer mortality in high-income and middle-income countries. Lancet 2016;388(10045):684–95.
65. Simons J. IBM, a pioneer of remote work, calls workers back to the office: Big Blue says move will improve collaboration and accelerate the pace of work. Wall St J 2017. Available at: https://www.wsj.com/articles/ibm-a-pioneer-of-remote-work-calls-workers-back-to-the-office-1495108802. Accessed September 10, 2020.
66. Kaufman HW, Chen Z, Niles J, et al. Changes in the Number of US Patients With Newly Identified Cancer Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic. JAMA Netw Open 2020; 3(8):e2017267.
67. Simons J. IBM, a pioneer of remote work, calls workers back to the office: Big Blue says move will improve collaboration and accelerate the pace of work. Wall St J 2017. Available at: https://www.wsj.com/articles/ibm-a-pioneer-of-remote-work-calls-workers-back-to-the-office-1495108802. Accessed September 10, 2020.
68. Thousands of healthcare workers are laid off or furloughed as coronavirus spreads. Los Angeles Times 2020; https://www.latimes.com/california/story/2020-05-02/coronavirus-california-healthcare-workers-layoffs-furloughs. Accessed September 8, 2020.
74. Paycheck Protection Program and Health Care Enhancement Act. Pub L No 116-139 (2020).
75. Demirjian NL, Fields BKK, Song C, et al. Impacts of the Coronavirus Disease 2019 (COVID-19) pandemic on healthcare workers: A nationwide survey of United States radiologists. Clin Imaging 2020; 68:218–25.
76. Shanafelt T, Ripp J, Trockel M. Understanding and Addressing Sources of Anxiety Among Health Care Professionals During the COVID-19 Pandemic. JAMA 2020;323(21):2133–4.
77. Restauri N, Sheridan AD. Burnout and Posttraumatic Stress Disorder in the Coronavirus Disease 2019 (COVID-19) Pandemic: Intersection, Impact, and Interventions. J Am Coll Radiol 2020;17(7):921–6.
78. Alvin MD, George E, Deng F, et al. The Impact of COVID-19 on Radiology Trainees. Radiology 2020; 296(2):246–8.
79. Kalia V, Srinivasan A, Wilkins L, et al. Adapting Scientific Conferences to the Realities Imposed by COVID-19. Radiol Imaging Cancer 2020;2(4):e204020.
80. Evens R. The impact of a pandemic on professional meetings. Radiol Imaging Cancer 2020;2(3). Available at: https://pubs.rsna.org/doi/10.1148/rycan.2020204012. Accessed October 2, 2020.
81. Vagal A, Reeder SB, Sodickson DK, et al. The Impact of the COVID-19 Pandemic on the Radiology Research Enterprise: Radiology Scientific Expert Panel. Radiology 2020;296(3):E134–40.
82. McDermott MM, Newman AB. Preserving clinical trial integrity during the coronavirus pandemic. JAMA 2020. https://doi.org/10.1001/jama.2020.4689.
83. FDA guidance on conduct of clinical trials of medical products during COVID-19 pandemic: guidance for industry, investigators, and institutional review boards. US Food and Drug Administration. 2020. Available at: https://www.fda.gov/media/136238/download. Accessed September 11, 2020.
84. Eary J, Shankar L. COVID-19 Update from the NCI Cancer Imaging Program. Radiol Imaging Cancer 2020;2(3):e204017.
85. Nabhan C, Choueiri TK, Mato AR. Rethinking Clinical Trials Reform During the COVID-19 Pandemic. JAMA Oncol 2020;6(9):1327–9.
86. COVID-19 and Cancer Consortium Registry (CCC19). ClinicalTrials.gov identifier: NCT04354701. 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT04354701?term=NCT04354701&draw=2&rank=1. Accessed September 11, 2020.
87. Bartsch SM, Ferguson MC, McKinnell JA, et al. The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States. Health Aff (Millwood) 2020;39(6):927–35.
88. Department of Labor. 2020. Available at: https://www.dol.gov/ui/data.pdf. Accessed September 10, 2020.
89. Cavallo JJ, Forman HP. The Economic Impact of the COVID-19 Pandemic on Radiology Practices. Radiology 2020;296(3):E141–4.